VERONA PHARMA PLC

Analyst Reco. Verona Pharma plc London S.E.

Equities

VRP

GB00BYW2KH80

Delayed London S.E. Other stock markets 12:35:15 2020-10-29 pm EDT			5-day change	1st Jan Change
55 ^GBX	+5.77%		+4.76%	-11.29%

Apr. 22	European Equities Traded in the US as American Depositary Receipts Rebound in Monday Trading	MT
Apr. 16	European Equities Traded in the US as American Depositary Receipts Lower in Tuesday Trading	MT

Analyst Reco.

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Piper Sandler Raises Verona Pharma's Price Target to $36 From $31, Keeps Overweight Rating	Apr. 16	MT
Wedbush Raises Verona Pharma Price Target to $33 From $30, Maintains Outperform Rating	23-09-13	MT
Truist Securities Adjusts Price Target on Verona Pharma to $32 From $28, Maintains Buy Rating	23-06-07	MT
Possibility of US Fed's Rate Hike Pause Supports American Depositary Receipts of European Equities	23-03-23	MT
BTIG Adjusts Price Target on Verona Pharma to $31 From $26, Maintains Buy Rating	23-03-20	MT
European Equities Move Lower Following ECB Rate Hike	23-02-02	MT
HC Wainwright Adjusts Verona Pharma's Price Target to $32 From $30, Keeps Buy Rating	22-12-21	MT
Wedbush Raises Verona Pharma's Price Target to $30 From $23, Maintains Outperform Rating	22-12-20	MT
Truist Securities Adjusts Price Target on Verona Pharma to $28 From $20, Maintains Buy Rating	22-12-20	MT
BTIG Boosts Price Target on Verona Pharma to $26 From $17, Reiterates Buy Rating	22-12-20	MT
ECB, Bank of England Interest Rate Hikes Weigh Down European Equities	22-12-15	MT
Wedbush Lowers Verona Pharma's Price Target to $23 From $27 Due to Increased Share Count, Keeps Outperform Rating	22-11-10	MT
Wedbush Analyst Assumes Coverage on Verona Pharma at Outperform With $27 Price Target, Up From $23	22-09-19	MT
HC Wainwright Adjusts Verona Pharma's Price Target to $30 From $25, Reiterates Buy Rating	22-08-29	MT
Piper Sandler Initiates Coverage on Verona Pharma With Overweight Rating, $31 Price Target	22-08-26	MT
Wedbush Raises Verona Pharma's Price Target to $23 From $18, Maintains Outperform Rating	22-08-09	MT
Wedbush Cuts Verona Pharma's Price Target to $18 From $25, Adjusting Ensifentrine Launch Estimates; Outperform Rating Kept	22-06-17	MT
Canaccord Genuity Adjusts Price Target on Verona Pharma to $23 From $18, Keeps Buy Rating	21-11-12	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

The best tools reserved for subscribers to boost the performance of your investments!

Optimize my profits

fermer